These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 696465

  • 1. Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.
    Riederer P, Youdim MB, Birkmayer W, Jellinger K.
    Adv Biochem Psychopharmacol; 1978; 19():377-82. PubMed ID: 696465
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB.
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [Abstract] [Full Text] [Related]

  • 3. (-)Deprenyl in the treatment of Parkinson's disease.
    Birkmayer W, Riederer P, Youdim MB.
    Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755
    [No Abstract] [Full Text] [Related]

  • 4. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
    Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MB.
    Adv Neurol; 1987; 45():111-8. PubMed ID: 3030067
    [Abstract] [Full Text] [Related]

  • 5. Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.
    Reiderer P, Reynolds GP.
    Br J Clin Pharmacol; 1980 Jan; 9(1):98-9. PubMed ID: 6766730
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Are there MAO inhibitors specific for dopamine metabolism?
    Youdim MB, Holzbauer M.
    Adv Biochem Psychopharmacol; 1977 Jan; 16():349-58. PubMed ID: 329649
    [No Abstract] [Full Text] [Related]

  • 9. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G, Földi P, Held G, Székely AM, Knoll J.
    Pol J Pharmacol Pharm; 1986 Jan; 38(1):57-67. PubMed ID: 3020531
    [Abstract] [Full Text] [Related]

  • 10. Selegiline for Parkinson's disease.
    Calesnick B.
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [Abstract] [Full Text] [Related]

  • 11. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002 Feb; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract] [Full Text] [Related]

  • 12. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB, Finberg JP.
    Adv Neurol; 1987 Feb; 45():127-36. PubMed ID: 3103383
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The possible mechanisms of action of (-)deprenyl in Parkinson's disease.
    Knoll J.
    J Neural Transm; 1978 Feb; 43(3-4):177-98. PubMed ID: 745011
    [No Abstract] [Full Text] [Related]

  • 15. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies.
    Langston JW.
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 61-6; discussion 67-9. PubMed ID: 2120617
    [No Abstract] [Full Text] [Related]

  • 16. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N, Damase-Michel C, Senard JM, Rascol O, Montastruc JL.
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [Abstract] [Full Text] [Related]

  • 17. Selegiline's neuroprotective capacity revisited.
    Riederer P, Lachenmayer L.
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract] [Full Text] [Related]

  • 18. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS, Fazzini E, Volkow ND.
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
    Cohen G, Spina MB.
    Ann Neurol; 1989 Nov; 26(5):689-90. PubMed ID: 2510589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.